Receptor research
Mazdutide and survodutide: GLP-1 and glucagon dual agonists for research
7 November 2026 · 6 min read
Incretin hormones have drawn researchers for years because a single signal can shape insulin secretion, gastric emptying and glucose handling all at once. A second line of work centres on glucagon, a hormone that pulls in almost the opposite direction. Dual agonists combine both worlds by activating the GLP-1 receptor and the glucagon receptor within one molecule. This guide looks at what these compounds show in models, how the glucagon receptor behaves and how mazdutide, survodutide and retatrutide differ from one another.
Why pair GLP-1 with glucagon
In models, GLP-1 suppresses glucagon secretion and boosts insulin release when glucose rises. Glucagon does the reverse in the liver, where it triggers glycogen breakdown and the production of glucose from precursors. On paper, those signals look contradictory.
Research also shows that glucagon influences energy expenditure and lipid metabolism, effects that GLP-1 signalling does not reproduce on its own. That is the logic behind a single molecule that carries both activities. The design lets a lab ask whether the combined effect is additive or whether it depends on how strongly each receptor is engaged.
The glucagon receptor and energy expenditure in models
The glucagon receptor is found mainly in the liver, with expression in the kidney and other tissues as well. In rodent studies, activating it was linked to higher energy expenditure, partly through thermogenesis in brown adipose tissue.
- in mouse and rat models, glucagon receptor activation increased energy expenditure,
- brown fat is studied as a site of thermogenesis, the production of heat,
- higher energy expenditure does not translate directly into body mass changes, because the outcome depends on the balance with food intake in a given protocol.
The last point matters when reading the literature. The mechanism alone does not decide the final result, which is why researchers measure food intake and activity alongside energy expenditure.
Liver models: glucose, lipids and steatosis
The liver is where glucagon and GLP-1 pathways meet. Glucagon promotes glycogenolysis and gluconeogenesis, and it also favours the oxidation of fatty acids. In models of hepatic steatosis, researchers have described shifts in lipid content within hepatocytes after both receptors are engaged.
Cultured hepatocytes are a common tool for these questions. They separate a compound’s direct effect on liver cells from the whole-body effects seen in animal work. Pairing a GLP-1 signal, which supports glucose homeostasis, with a glucagon signal makes it possible to compare the hepatic profile of a dual agonist against single-receptor analogues.
Mazdutide: GLP-1 and glucagon in one molecule
Mazdutide, also known in the literature as IBI362 or LY3305677, is a dual agonist of the GLP-1 and glucagon receptors. It has been studied in clinical research. At MOLEVIA it is sold as a research reagent in 5 mg and 10 mg vials.
Typical lines of analysis include glucose handling, body mass changes in models and the lipid profile of the liver. For a lab that wants to see a dual agonist without a third receptor in the mix, mazdutide is a clean starting point.
Survodutide: balancing two receptors in practice
Survodutide, known as BI 456906, is a dual agonist of the glucagon and GLP-1 receptors and has also been studied clinically. At MOLEVIA it is available as a 10 mg research vial.
With this compound, the order of questions matters. Does the observed effect come from the GLP-1 receptor or from the glucagon receptor? The answer comes from experiments that block one receptor and compare results with single-receptor agonists. Without that design, a result cannot show which pathway drives the change.
Retatrutide: three receptors on one chain
Retatrutide (LY3437943) is a triple agonist of the GIP, GLP-1 and glucagon receptors. It was studied in a phase 2 and phase 3 clinical programme. The peptide has around 39 amino acids and a lipid chain that binds it to albumin in circulation.
Catalogue data includes CAS number 2381089-83-2, formula C221H342N46O68 and a mass of 4731.3 Da. Retatrutide is offered in 5 mg to 100 mg vials, so a lab can match the quantity to the scale of its experiment. Researchers looking to buy retatrutide for research will find it listed in the incretin analogues category.
The main difference from the dual agonists is the extra GIP receptor. In models, it allows a lab to test how the response shifts when a third pathway joins the GLP-1 and glucagon signals.
Side-by-side comparison
| Compound | Receptors | Research status per literature | Vial sizes at MOLEVIA |
|---|---|---|---|
| Mazdutide | GLP-1, glucagon | studied clinically | 5 mg, 10 mg |
| Survodutide | glucagon, GLP-1 | studied clinically | 10 mg |
| Retatrutide | GIP, GLP-1, glucagon | phase 2 and phase 3 clinical programme | 5 mg to 100 mg |
The takeaway is straightforward. Mazdutide and survodutide let a lab study how two receptors cooperate, while retatrutide adds a third pathway that has to be included in any interpretation. The right choice depends on the research question, not on the receptor count alone.
From delivery to data: working in the lab
- Identity: mass spectrometry confirms the molecular mass, which should be the first check on arrival.
- Purity: HPLC results at MOLEVIA reach 99% or higher for every batch.
- Storage: keep the lyophilised powder as the product card describes, away from moisture and light.
- Records: log the batch number with every experiment, because batch-to-batch differences often explain unexpected results.
Ordering and delivery
- Orders placed by 2 p.m. on a working day ship the same day.
- InPost Paczkomat in Poland: delivery on the next working day.
- DPD across Europe: 2-4 working days, with shipping to 29 countries.
- Free shipping from 75 EUR, 65 GBP, 80 USD.
- Volume discounts apply automatically: 2 pieces save 5%, 3 pieces save 10%, 5 pieces save 15%.
- Orders from 50 EUR (40 GBP, 55 USD) that include a peptide vial also get a free 10 ml vial of bacteriostatic water.
- Pay online by card, Apple Pay, Google Pay or BLIK (PLN only).
Key takeaways
- Dual GLP-1 and glucagon agonists combine signals that point in different directions in models.
- The glucagon receptor is central to research on energy expenditure and the liver.
- Mazdutide and survodutide are dual agonists, while retatrutide adds a GIP receptor.
- Comparing results requires the same method and the same batch of reagent.
- Every batch carries purity of 99% or higher (HPLC), confirmed mass (MS).
- All products are research reagents for laboratory use only (Research Use Only), available in the shop.